Research programme: cancer therapy adjuvants - VG Life Sciences

Drug Profile

Research programme: cancer therapy adjuvants - VG Life Sciences

Alternative Names: 2-deoxyglucose/etomoxir - MetaCytoLytics; Dichloroacetic acid - MetaCytoLytics; MDT compounds - MetaCytoLytics

Latest Information Update: 30 Nov 2012

Price : $50

At a glance

  • Originator University of Colorado Foundation; University of Vermont
  • Developer VG Life Sciences
  • Class Acetates; Deoxy sugars; Epoxy compounds
  • Mechanism of Action Antimetabolites; Carnitine O-palmitoyltransferase inhibitors; Enzyme inhibitors; Glucose modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 30 Nov 2012 Viral Genetics is now called VG Life Sciences
  • 23 May 2012 Viral Genetics plans a clinical trial for Ovarian cancer (adjuvant therapy, late-stage disease) in USA
  • 15 Feb 2011 Development is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top